Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide ; volume:61 ; number:7 ; day:8 ; month:6 ; year:2022 ; pages:1057-1067 ; date:7.2022
Clinical pharmacokinetics ; 61, Heft 7 (8.6.2022), 1057-1067, 7.2022
- Creator
-
Urva, Shweta
Quinlan, Tonya
Landry, John
Ma, Xiaosu
Martin, Jennifer A.
Benson, Charles T.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-022-01140-3
- URN
-
urn:nbn:de:101:1-2022092107114527331947
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Urva, Shweta
- Quinlan, Tonya
- Landry, John
- Ma, Xiaosu
- Martin, Jennifer A.
- Benson, Charles T.
- SpringerLink (Online service)
Other Objects (12)
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Interaktion der GLP-1- und GIP-Rezeptoren
Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Exendin-3-Derivate als GLP-1-Rezeptor-Agonisten
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Neue Antidiabetika – Neuer GLP-1-Agonist für mehr Lebensqualität
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Interaktion der GLP-1- und GIP-Rezeptoren
Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Exendin-3-Derivate als GLP-1-Rezeptor-Agonisten
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Neue Antidiabetika – Neuer GLP-1-Agonist für mehr Lebensqualität
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Interaktion der GLP-1- und GIP-Rezeptoren
Dual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Exendin-3-Derivate als GLP-1-Rezeptor-Agonisten
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Tirzepatid: GIP-/GLP-1-Rezeptoragonist zur Therapie des Typ-2-Diabetes – SURPASS-Studienprogramm
Neue Antidiabetika – Neuer GLP-1-Agonist für mehr Lebensqualität